Abdala, the first Cuban and Latin American vaccine against covid-19, celebrates this Saturday the first anniversary of its approval by the local regulatory authority for its emergency use in the mass immunization campaign on the island.
This vaccine -created and manufactured by the Center for Genetic Engineering and Biotechnology (CIGB)- has shown an efficacy of 92.28% in clinical trials. In its last phase of testing, 48,000 volunteers aged 19 to 80 participated.
–
Related posts:
Colorado Avalanche Forward Valeri Nichushkin Absent from Team Activities for Personal Reasons
A new tool in the fight against cancer makes its appearance in the clinical setting: the liquid biop...
[Avviso]For European Economic Area (EEA) and UK Customers - Yahoo! JAPAN
Babies in Singapore Born with COVID-19 Antibodies, What Causes It?
:quality(80)/cdn-kiosk-api.telegraaf.nl/6d20b3dc-ffc1-11ec-bf4a-02d1dbdc35d1.jpg?resize=150%2C150&ssl=1 "British media: several candidates apply for premiership | Abroad")